[ad_1]
A recent Financial Times article sparked riots among investors on the stock exchanges, which dealt with a setback in the fight against coronavirus: The active ingredient remdesivir reportedly failed in a clinical study as a remedy for lung-induced lung disease. Covid-19 virus. The newspaper referred to a summary of the study that was briefly available on the WHO website.
Clemens Wendtner, chief physician at the Schwabing Clinic in Munich, has a different view on the subject: the drug has had initial success in patients at his hospital. According to conservative estimates, half of his patients have benefited, Wendtner said. It seems that seriously ill people could withdraw from the fans sooner.
The manufacturer of remdesivir Gilead Sciences of the EE. USA It also rejected reports of the ruling. There was no approval for publication. The study was terminated prematurely due to low participation, so no statistically significant conclusions were possible. “In this regard, the study results are inconclusive, although the trends in the data suggest a potential benefit for remdesivir, particularly in patients receiving early disease treatment,” the company said. The study results are expected in late May.
Research competition
The crown pandemic has triggered an unprecedented global research career. New results are released almost daily, but no progress has yet been made. Also in Austria, drugs such as antivirals, immunomodulators, and drugs for lung patients are used in experimental cure trials and in clinical trials. Time and again it turns out that hopeful approaches do not bring the desired success. One of the drugs that is out of the running is the anti-malaria drug hydroxychloroquine.
